Revvity Inc/ US7140461093 /
| 2024-06-11 9:59:53 PM | Chg. +0.40 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 109.70USD | +0.37% | 36,830 Turnover: 4.02 mill. |
-Bid Size: - | -Ask Size: - | 13.54 bill.USD | 0.26% | 19.73 |
GlobeNewswire
06-03
Orion is developing the Finnish life science industry in a unique collaboration project
GlobeNewswire
05-28
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Grea...
GlobeNewswire
05-09
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific N...
GlobeNewswire
01-19
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Pan...
GlobeNewswire
01-08
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend
GlobeNewswire
2023-11-30
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD
GlobeNewswire
2023-11-13
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. -...
GlobeNewswire
2023-11-05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - ...
GlobeNewswire
2021-05-18
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study...
GlobeNewswire
2021-05-11
Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunol...
GlobeNewswire
2021-04-29
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell R...
